Kura Oncology, Inc. (NASDAQ:KURA) Insider Sells $39,058.81 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Kura Oncology Stock Up 4.4 %

NASDAQ:KURA opened at $8.03 on Friday. The firm has a market capitalization of $624.41 million, a price-to-earnings ratio of -3.40 and a beta of 0.81. Kura Oncology, Inc. has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business’s fifty day moving average price is $9.02 and its 200 day moving average price is $15.58.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period last year, the business earned ($0.50) EPS. On average, sell-side analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Rhumbline Advisers boosted its stake in shares of Kura Oncology by 2.0% during the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company’s stock worth $871,000 after acquiring an additional 1,923 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of Kura Oncology in the 4th quarter worth approximately $623,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after acquiring an additional 1,750 shares during the period. Moody Aldrich Partners LLC lifted its position in shares of Kura Oncology by 42.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after acquiring an additional 42,712 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Kura Oncology in the 4th quarter worth approximately $436,000.

Analysts Set New Price Targets

Several equities research analysts recently commented on KURA shares. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and dropped their target price for the company from $26.00 to $19.00 in a report on Monday, October 14th. Wedbush reiterated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Tuesday, November 19th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.38.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.